The Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) organizational structure includes a number of internal and external advisory committees to provide input into strategic planning for development and implementation of the scientific goals of the center. The external scientific advisory group is the Scientific External Advisory Board (EAB), which is composed of scientific experts and leaders from other major cancer centers. In addition to the standing external advisory membership, ad hoc advisors are added to the roster periodically to assess and advise regarding specific programs, shared resources, or inter-programmatic activities. Internal planning and evaluation is a continuous process at MCC that occurs through meetings of the Associate Directors (1st Tuesday of the month), and combined Associate Directors and Program Leaders meetings (3rd Tuesday of the month), and the Senior Advisory Committee (SAC) meetings (2nd Tuesday of the month). It is a policy of MCC that each program has an annual strategic planning retreat. These retreats are supported by MCC funding and provide a forum for more extended scientific interchange as well as membership input into plans for increasing the scientific and translational opportunities of the program through future faculty recruitment, shared resource development, and other mechanisms for increased scientific productivity and collaboration. MCC-wide planning retreats are held in conjunction with the annual all-center scientific retreats as a forum for all members to participate in MCC planning.
Continuing self-evaluation and reappraisal is needed to ensure that MCC is best fulfilling its public health mission. The Program Planning and Evaluation component of the CCSG provides the MCC Director with both internal and external reviews and recommendations against which strategic decisions can be made. The component also supports the individual programs in their own annual, strategic planning.
|Ma, Yibao; Min, Hae-Ki; Oh, Unsong et al. (2017) The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals. J Biol Chem 292:20989-20997|
|van der Weyden, Louise; Arends, Mark J; Campbell, Andrew D et al. (2017) Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature 541:233-236|
|Schurman, Lesley D; Smith, Terry L; Morales, Anthony J et al. (2017) Investigation of left and right lateral fluid percussion injury in C57BL6/J mice: In vivo functional consequences. Neurosci Lett 653:31-38|
|Newton, Jason; Hait, Nitai C; Maceyka, Michael et al. (2017) FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts. FASEB J 31:1719-1730|
|Manzanares, Miguel Á; Usui, Akihiro; Campbell, Deanna J et al. (2017) Transforming Growth Factors ? and ? Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model. Am J Pathol 187:1068-1092|
|Arsenovic, Paul T; Mayer, Carl R; Conway, Daniel E (2017) SensorFRET: A Standardless Approach to Measuring Pixel-based Spectral Bleed-through and FRET Efficiency using Spectral Imaging. Sci Rep 7:15609|
|Lownik, Joseph C; Luker, Andrea J; Damle, Sheela R et al. (2017) ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses. J Immunol 199:2305-2315|
|Karki, Kishor; Saraiya, Siddharth; Hugo, Geoffrey D et al. (2017) Variabilities of Magnetic Resonance Imaging-, Computed Tomography-, and Positron Emission Tomography-Computed Tomography-Based Tumor and Lymph Node Delineations for Lung Cancer Radiation Therapy Planning. Int J Radiat Oncol Biol Phys 99:80-89|
|Meier, Jeremy A; Hyun, Moonjung; Cantwell, Marc et al. (2017) Stress-induced dynamic regulation of mitochondrial STAT3 and its association with cyclophilin D reduce mitochondrial ROS production. Sci Signal 10:|
|Benson, Zachary; Manjili, Saeed H; Habibi, Mehran et al. (2017) Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochem Pharmacol 145:12-17|
Showing the most recent 10 out of 499 publications